Home › NDC Lookup › Ingredients › Cyanocobalamin › 70069-0172-10
cyanocobalamin 1000 ug/mL Injection — NDC 70069-0172-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

cyanocobalamin 1000 ug/mL Injection — NDC 70069-172-10 (Billing 70069-0172-10)

by Somerset Therapeutics, LLC · 10 VIAL in 1 CARTON / 10 mL in 1 VIAL

This is a package of cyanocobalamin 1000 ug/mL Injection from Somerset Therapeutics, LLC, marketed since Jun 2017 and currently FDA-listed; retail pharmacies pay about $0.7386 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 70069-0172-10
🏷️ FDA NDC (as labeled) 70069-172-10 billing pads the product segment with a zero
This package
Contains10 mL in 1 vial Cost per mL$0.7386 NADAC Per package$73.86 / 100 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $2.51/unit — full pricing hub ↓
Main listing for product 70069-172 · Also comes in: 25 vials 70069-172-25
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Cyanocobalamin (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jul 24, 2026 — Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde (American Regent, Inc.) · FDA recall D-0793-2026
Class II · Jul 24, 2026 — Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde (American Regent, Inc.) · FDA recall D-0792-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70069-172-10
Product NDC 70069-172
11-digit billing NDC 70069017210
NCPDP billing unit ML — per mL (volume)
RxCUI 309594
UNII P6YC3EG204
UPC 0370069172018, 0370069172100, 0370069005019, 0370069005101 +1 more
Application # ANDA206503
SPL Set ID 41ac0dc1-0a71-4c69-8e25-ba838f5f16a3
Established class (EPC) Vitamin B12
Chemical class Vitamin B 12
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-06-27
Route INTRAMUSCULAR, SUBCUTANEOUS
Dosage form INJECTION
Substance CYANOCOBALAMIN
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 82100010002015
GPI class Cyanocobalamin
GCN Seq No 002329
GCN 94594
HICL code 001053
Ingredient (HICL) Cyanocobalamin (Vitamin B-12)
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C6
Therapeutic class — intermediate (HIC2) Vitamins
HIC3 code C6L
Therapeutic class — specific (HIC3) Vitamin B12 Preparations
AHFS code 88:08.00.00
AHFS class Vitamin B Complex
FDB label name CYANOCOBALAMIN 10,000 MCG/10ML
FDB brand name Cyanocobalamin Injection
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 002329
  • GCN: 94594
  • GPI-14 (Medi-Span): 82100010002015
  • HICL (First Databank): 001053
  • AHFS class code: 88:08.00.00
  • RxCUI (RxNorm): 309594
Why two NDCs? The FDA registers this code as 70069-172-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70069-0172-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Vitamin B12 class.

Pharmacologic class Vitamin B12
Drug family (ATC) Vitamin B12 (cyanocobalamin and analogues)
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CYANOCOBALAMIN 10,000 MCG/10ML Ingredient Cyanocobalamin (Vitamin B-12)
📗 Our plain-language guide HelloPharmacist
  • It replaces vitamin B12 when you are low. Doctors use it for deficiency from poor absorption, pernicious anemia, or a diet low in B12. The injection and the nasal spray are approve...
  • The usual approach is one spray in one nostril once a week. Use it at least an hour before or after hot foods or drinks. Follow your prescriber and your product label.
  • Some injection products are labeled to be given by a healthcare professional and not for self-administration. Ask your prescriber how yours should be given. It should never go into...
  • With the nasal spray, people reported colds, headache, weakness, nausea, a sore tongue, tingling and a runny nose. Call your doctor about anything that bothers you. Get emergency h...
📖 Read our full Cyanocobalamin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.739 $73.86 / 100 ml
Medicaid paysCMS SDUD · 12 mo $2.51 $251.08 / 100 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J3420 $0.683 / J3420 unit —
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Aug 2022 Feb 2026 Sep 2026 $1.444 $0.739
▼ Down 27% over the last 21 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)70069-172-10
11-digit billing NDC70069-0172-10
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ3420
DescriptorINJECTION, VITAMIN B-12 CYANOCOBALAMIN, UP TO 1000 MCG
Billing units / pkg1 units
How the units are derivedThis package is 10 ML; the HCPCS unit is 1000 MCG, so one package = 1 billing unit.
Medicare Part B spend (2026 (Q1))$219,225 · 343,052 claims · $0.64 per claim (all NDCs under J3420)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
70069-0172-10 You're viewing this Main listing 10 VIAL in 1 CARTON / 10 mL in 1 VIAL $0.7386 / mL $73.86 2017-06-27 — Active
70069-0172-25 70069-172-25 25 VIAL in 1 CARTON / 10 mL in 1 VIAL — — 2017-06-27 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 vial in 1 carton / 10 ml in 1 vial.
What NDC number is used to bill for this package of cyanocobalamin 1000 ug/mL Injection?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cyanocobalamin 1000 ug/mL 00143-9619-10 Hikma 10 vials $0.328 AP Availability likely save 56%
Cyanocobalamin 1000 ug/mL 69680-0121-05 Vitruvias 5 vials $0.552 AP Availability likely save 25%
Cyanocobalamin 1000 ug/mL 00143-9620-10 Hikma 10 vials $0.739 AP Availability likely —
Cyanocobalamin 1000 ug/mL 69680-0113-99 Vitruvias 10 vials $0.739 AP Availability likely —
cyanocobalamin 1000 ug/mLthis 70069-0172-10 Somerset 10 vials $0.739 AP Availability likely —
Cyanocobalamin 1000 ug/mL 71288-0301-11 Meitheal 10 vials $0.739 AP Availability likely —
cyanocobalamin 1000 ug/mL 70710-1665-01 Zydus 1 vial $0.761 AP Availability likely +3%
Cyanocobalamin 1000 ug/mL 00517-0130-01 American 1 vial $0.787 AP Availability likely +7%
Cyanocobalamin 1000 ug/mL 71288-0302-30 Meitheal 1 vial $0.787 AP Availability likely +7%
cyanocobalamin 1000 ug/mL 70710-1664-06 Zydus 10 vials $0.819 AP Availability likely +11%
Cyanocobalamin 1000 ug/mL 00143-9621-25 Hikma 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 00517-0031-25 American 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 25021-0502-01 Sagent 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 63323-0044-01 Fresenius 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 68001-0542-60 BluePoint 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 68001-0640-60 BluePoint 25 vials $1.474 AP Availability likely +100%
cyanocobalamin 1000 ug/mL 70069-0005-10 Somerset 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 70512-0840-25 SOLA 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 71288-0300-92 Meitheal 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 71288-0303-02 Meitheal 25 vials $1.474 AP Availability likely +100%
Cyanocobalamin 1000 ug/mL 72603-0650-25 NorthStar 25 vials $1.474 AP Availability likely +100%
cyanocobalamin 1000 ug/mL 70710-1663-07 Zydus 25 vials $1.491 AP Availability likely +102%
Cyanocobalamin 1000 ug/mL 00517-0032-25 American 25 vials $2.134 AP Availability likely +189%
Cyanocobalamin 1000 ug/mL 69680-0112-10 Vitruvias 10 vials $2.970 AP Availability likely +302%
Cyanocobalamin 1000 ug/mL 00404-9783-30 Henry 1 vial — AP FDA listed —
Cyanocobalamin 1000 ug/mL 00404-9786-10 Henry 1 vial — AP FDA listed —
Cyanocobalamin 1000 ug/mL 50090-6229-00 A-S 25 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 51662-1394-01 HF 30 ml — AP FDA listed —
Cyanocobalamin 1000 ug/mL 51662-1440-01 HF 10 ml — AP FDA listed —
Cyanocobalamin 1000 ug/mL 51662-1647-03 HF 25 pouches — AP FDA listed —
Cyanocobalamin 1000 ug/mL 51662-1703-03 HF 10 pouches — AP FDA listed —
Cyanocobalamin 1000 ug/mL 55150-0364-01 AuroMedics 1 vial — AP FDA listed —
Cyanocobalamin 1000 ug/mL 68083-0449-25 Gland 25 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 68083-0561-25 Gland 25 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 68083-0562-01 Gland 1 vial — AP FDA listed —
Cyanocobalamin 1000 ug/mL 70069-0171-05 Somerset 5 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 70756-0635-10 Lifestar 10 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 70756-0636-10 Lifestar 10 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 70756-0637-05 Lifestar 5 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 70771-1688-07 Zydus 25 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 70771-1689-06 Zydus 10 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 70771-1690-01 Zydus 1 vial — AP FDA listed —
cyanocobalamin 1000 ug/mL 76420-0075-25 Asclemed 25 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 76420-0111-25 Asclemed 25 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 76420-0618-25 Asclemed 25 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 85766-0029-25 Sportpharm 25 vials — AP FDA listed —
Cyanocobalamin 1000 ug/mL 87188-0111-90 Plano 25 vials — AP FDA listed —
cyanocobalamin 1000 ug/mL 87188-0112-01 Plano 1 vial — AP FDA listed —
cyanocobalamin 1000 ug/mL 87188-0113-01 Plano 1 vial — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Jun 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Red
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 15 mg / 1 mL UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • 9 mg / 1 mL UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSomerset Therapeutics, LLC
Application holderSOMERSET THERAPEUTICS LLC
FDA applicationANDA206503 (ANDA)
Labeler code70069
First marketedJun 2017
Product typeHuman Prescription Drug
Portfolio184 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 158 words ▾

INDICATIONS AND USAGE Cyanocobalamin is indicated for Vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue.

Such measures remove the need for long-term administration of cyanocobalamin. Requirements of Vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the Vitamin B 12 absorption test (Schilling test).

⏱️ Dosage and Administration 218 words ▾

DOSAGE AND ADMINISTRATION Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine. Pernicious Anemia Parenteral Vitamin B 12 is the recommended treatment and will be required for the remainder of the patient's life.

The oral form is not dependable. A dose of 100 mcg daily for six or seven days should be administered by intramuscular or deep subcutaneous injection. If there is clinical improvement and if a reticulocyte response is observed, the same amount may be given on alternate days for seven doses, then every three to four days for another two to three weeks.

By this time hematologic values should have become normal. This regimen should be followed by 100 mcg monthly for life. Folic acid should be administered concomitantly if needed.

Patients with Normal Intestinal Absorption Where the oral route is not deemed adequate, initial treatment similar to that for patients with pernicious anemia may be indicated depending on the severity of the deficiency. Chronic treatment should be with an oral B 12 preparation. If other vitamin deficiencies are present, they should be treated.

Schilling Test The flushing dose is 1,000 mcg. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

⛔ Contraindications 11 words ▾

CONTRAINDICATIONS Sensitivity to cobalt and/or Vitamin B 12 is a contraindication.

⚠️ Warnings 181 words ▾

WARNINGS This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Patients with early Leber's disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy.

Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely. Anaphylactic shock and death have been reported after parenteral Vitamin B 12 administration. An intradermal test dose is recommended before cyanocobalamin injection is administered to patients suspected of being sensitive to this drug.

This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal ''Gasping Syndrome'' in premature infants.

🤒 Adverse Reactions 51 words ▾

ADVERSE REACTIONS Generalized Anaphylactic shock and death have been reported with administration of parenteral Vitamin B 12 (see WARNINGS ). Cardiovascular Pulmonary edema and congestive heart failure early in treatment; peripheral vascular thrombosis. Hematological Polycythemia vera. Gastrointestinal Mild transient diarrhea. Dermatological Itching; transitory exanthema. Miscellaneous Feeling of swelling of entire body.

🤰 Pregnancy 57 words ▾

Pregnancy Adequate and well-controlled studies have not been done in pregnant women. However, Vitamin B 12 is an essential vitamin and requirements are increased during pregnancy. Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for pregnant women (4 mcg daily) should be consumed during pregnancy.

🧒 Pediatric Use 28 words ▾

Pediatric Use Intake in children should be in the amount (0.5 to 3 mcg daily) recommended by the Food and Nutrition Board, National Academy of Science-National Research Council.

🆘 Overdosage 9 words ▾

OVERDOSAGE No overdosage has been reported with this drug.

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY Vitamin B 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis. Cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection; the plasma level of the compound reaches its peak within one hour after intramuscular injection. Absorbed Vitamin B 12 is transported via specific B 12 binding proteins, transcobalamin I and II to the various tissues.

The liver is the main organ for Vitamin B 12 storage. Within 48 hours after injection of 100 or 1,000 mcg of Vitamin B 12 , 50 to 98% of the injected dose may appear in the urine. The major portion is excreted within the first eight hours.

Intravenous administration results in even more rapid excretion with little opportunity for liver storage. Gastrointestinal absorption of Vitamin B 12 depends on the presence of sufficient intrinsic factor and calcium ions. Intrinsic factor deficiency causes pernicious anemia, which may be associated with subacute combined degeneration of the spinal cord.

Prompt parenteral administration of Vitamin B 12 prevents progression of neurologic damage. The average diet supplies about 5 to 15 mcg/day of Vitamin B 12 in a protein-bound form that is available for absorption after normal digestion. Vitamin B 12 is not present in foods of plant origin, but is abundant in foods of animal origin.

In people with normal absorption, deficiencies have been reported only in strict vegetarians who consume no products of animal origin (including no milk products or eggs). Vitamin B 12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum in the presence of calcium, and Vitamin B 12 enters the mucosal cell for absorption. It is then transported by the transcobalamin binding proteins.

A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. Oral absorption is considered too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption of Vitamin B 12 . Cyanocobalamin is the most widely used form of Vitamin B 12 , and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract.

Hydroxocobalamin is equally as effective as cyanocobalamin, and they share the cobalamin molecular structure.

📦 How Supplied / Storage and Handling 97 words ▾

HOW SUPPLIED NDC Number Cyanocobalamin mcg/mL Volume 70069- 005 -10 1,000 1 mL 70069- 172 -10 10 mL 70069- 172 -25 1 mL multiple dose vial, packaged 25 vials per tray. 10 mL multiple dose vial, packaged as; - 10 vials per tray and - 25 vials per tray. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

PROTECT FROM LIGHT Use only if solution is clear and seal intact. For Product Inquiry call 1-800-417-9175 Manufactured for: Somerset Therapeutics, LLC Somerset, NJ 08873 Made in India Code No.: KR/DRUGS/KTK/28/289/97 ST-CYC/P/06 Revised: 04/2025 1201236

📋 Description 109 words ▾

DESCRIPTION Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous use. Each mL contains 1,000 mcg cyanocobalamin; sodium chloride 0.9%; benzyl alcohol 1.5%; Water for Injection q.s.; Hydrochloric acid and/or sodium hydroxide for pH adjustment if necessary (4.5-7.0). Cyanocobalamin appears as dark, red crystals or as an amorphous or crystalline, red powder.

It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). It is stable to autoclaving for short periods at 121°C. The Vitamin B 12 coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide. The cobalt content is 4.34%. The structural formula is represented below: Molecular Structure

💬 Information for Patients 165 words ▾

Information for Patients Patients with pernicious anemia should be instructed that they will require monthly injections of Vitamin B 12 for the remainder of their lives. Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of Vitamin B 12 , because the former may prevent anemia but allow progression of subacute combined degeneration.

A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any Vitamin B 12 . Patients following such a diet should be advised to take oral Vitamin B 12 regularly. The need for Vitamin B 12 is increased by pregnancy and lactation.

Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time. Contains no more than 57 mcg/L of aluminum.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Vitamin B 12 deficiency that is allowed to progress for longer than three months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg/day may result in hematologic remission in patients with Vitamin B 12 deficiency. Neurologic manifestations will not be prevented with folic acid, and if not treated with Vitamin B 12 , irreversible damage will result.

Doses of cyanocobalamin exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis. Information for Patients Patients with pernicious anemia should be instructed that they will require monthly injections of Vitamin B 12 for the remainder of their lives.

Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of Vitamin B 12 , because the former may prevent anemia but allow progression of subacute combined degeneration. A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any Vitamin B 12 .

Patients following such a diet should be advised to take oral Vitamin B 12 regularly. The need for Vitamin B 12 is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.

Contains no more than 57 mcg/L of aluminum. Laboratory Tests During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary. Hematocrit, reticulocyte count, Vitamin B 12 , folate and iron levels should be obtained prior to treatment.

Hematocrit and reticulocyte counts should be repeated daily from the 5 th to 7 th days of therapy and then frequently until the hematocrit is normal. If folate levels are low, folic acid should also be administered. If reticulocytes have not increased after treatment or if reticulocyte counts do not continue at least twice normal as long as the hematocrit is less than 35%, diagnosis or treatment should be reevaluated.

Repeat determinations of iron and folic acid may reveal a complicating illness that might inhibit the response of the marrow. Patients with pernicious anemia have about three times the incidence of carcinoma of the stomach as the general population, so appropriate tests for this condition should be carried out when indicated. Drug and Laboratory Test Interactions Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and Vitamin B 12 diagnostic blood assays.

Colchicine, para-aminosalicylic acid and heavy alcohol intake for longer than two weeks may produce malabsorption of Vitamin B 12 . Carcinogenesis, Mutagenesis Long-term studies in animals to evaluate carcinogenic potential have not been done. There is no evidence from long-term use in patients with pernicious anemia that cyanocobalamin is carcinogenic.

Pernicious anemia is associated with an increased incidence of carcinoma of the stomach, but this is believed to be related to the underlying pathology and not to treatment with cyanocobalamin. Pregnancy Adequate and well-controlled studies have not been done in pregnant women. However, Vitamin B 12 is an essential vitamin and requirements are increased during pregnancy.

Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for pregnant women (4 mcg daily) should be consumed during pregnancy. Nursing Mothers Vitamin B 12 is known to be excreted in human milk. Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women (4 mcg daily) should be consumed during lactation.

Pediatric Use I… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 44 words ▾

Nursing Mothers Vitamin B 12 is known to be excreted in human milk. Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women (4 mcg daily) should be consumed during lactation.

📄 Package Label / Principal Display Panel 99 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Cyanocobalamin Injection, USP 1 mL Container Label NDC 70069- 005 -01 Container Label Cyanocobalamin Injection, USP 1 mL Carton Label NDC 70069- 005 -10 Carton Label Cyanocobalamin Injection, USP 10 mL Container Label NDC 70069- 172 -01 container Label Cyanocobalamin Injection, USP 10 mL Carton Label – Pack of 10's NDC 70069- 172 -10 carton label Cyanocobalamin Injection, USP 10 mL Carton Label – Pack of 25's NDC 70069- 172 -25 carton-label 1 mL Container label 1 mL Carton Label 10 mL container Label 10 mL carton label Carton Label - pack of 25 vials

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.4K
Units reimbursed last 4 qtrs
4.7K
Gross reimbursed last 4 qtrs
$11.8K
Avg / prescription
$8.45
Avg / unit
$2.5109
Latest quarter Q1 2026
226Rx
Medicaid pays / mL
$2.5109
gross reimbursed
vs
NADAC / mL
$0.7386
acquisition cost
=
Spread
+$1.7723
+240% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
48% FFS 52% MCO
Fee-for-service · 668 Rx Managed care · 729 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: 14 units · 0.7 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 780 units · 4.0 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 122 units · 3.8 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 81 units · 1.2 per 100k residents IN Ohio: no data reported OH Pennsylvania: 139 units · 1.1 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 2,465 units · 6.3 per 100k residents CA Utah: no data reported UT Colorado: 36 units · 0.6 per 100k residents CO Nebraska: no data reported NE Missouri: 5 units · 0.1 per 100k residents MO Kentucky: 283 units · 6.3 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 186 units · 5.1 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: 67 units · 2.2 per 100k residents AR Tennessee: 41 units · 0.6 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 79 units · 2.7 per 100k residents MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.16.3
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 6.3 /100k
2 Kentucky 6.3 /100k
3 Connecticut 5.1 /100k
4 New York 4.0 /100k
5 Nevada 3.8 /100k
6 Mississippi 2.7 /100k
7 Arkansas 2.2 /100k
8 Indiana 1.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
10 vials this page70069-0172-10 1,397 Rx · $11,801
25 vials70069-0172-25 No Medicaid data
Drug total (last 4 qtrs): 1,397 Rx · 4,700 units · $11,801 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 70069-0171-05 · Somerset 70069-0181-01 · Somerset →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.